Tag Archives: GLP-1 receptor agonists

GLP-1 receptor agonists have transformed the treatment of type 2 diabetes, but their effects on gastrointestinal motility remain an important clinical consideration. Opioids can also slow gastrointestinal function, raising an obvious question: what happens when patients need both? New research examining GLP-1 and opioid interactions suggests that opioid choice may …

GLP-1 receptor agonists have transformed type 2 diabetes and obesity treatment, but a rare vision safety signal deserves clinicians’ attention. Emerging evidence has raised concerns about a potential NAION risk with GLP-1 therapy, particularly with semaglutide (Ozempic, Rybelsus, and Wegovy). Non-arteritic anterior ischemic optic neuropathy (NAION) can cause sudden, usually …

Could a stool sample someday help clinicians choose a diabetes medication before writing the prescription? Emerging research into gut biomarkers in diabetes is moving that possibility closer to clinical reality. Rather than simply cataloging which bacteria live in the intestine, researchers are examining microbial genes, stool-derived metabolites, and functional signatures …

For years, lowering LDL cholesterol has been the cornerstone of preventing heart disease in people with diabetes. Statins and other cholesterol-lowering therapies have dramatically reduced cardiovascular events. Yet many patients continue to experience heart attacks, strokes, or other cardiovascular complications despite reaching recommended LDL cholesterol goals. Why does this happen? …

Finding the right diabetes medication often involves trial and error. One patient may respond well to a GLP-1 receptor agonist, while another sees little benefit from the same treatment. As a result, clinicians frequently adjust medications before finding the most effective option. What if doctors could test a patient’s response …

Diabetes research has advanced rapidly over the past two decades, leading to groundbreaking medications such as GLP-1 receptor agonists, SGLT2 inhibitors, and dual incretin therapies. However, one challenge remains constant: developing new treatments through traditional clinical trials is often expensive, time-consuming, and inflexible. Could there be a better way to …

Imagine prescribing the same diabetes medication to two patients with nearly identical A1C levels, only to see one achieve excellent glycemic control while the other experiences little benefit or troublesome side effects. This scenario is common in diabetes care and highlights an important question: could genetics explain these differences? Growing …

Not long ago, diabetes management focused primarily on controlling blood glucose levels. Today, that approach has evolved dramatically as cardiologists and endocrinologists increasingly work together to reduce cardiovascular risk. Thanks to groundbreaking cardiovascular outcome trials (CVOTs), clinicians now understand that treating type 2 diabetes means protecting the heart, kidneys, and …

For years, glucagon-like peptide-1 (GLP-1) receptor agonists have dominated conversations about diabetes and obesity treatment. However, another hormone is quietly returning to the spotlight. Amylin diabetes therapy is making a comeback as researchers develop a new generation of drugs designed to improve blood glucose control and support weight management. Amylin …

For many people living with binge eating disorder and type 2 diabetes, managing blood sugar isn’t just about counting carbohydrates or losing weight. Emotional eating, loss of control around food, and feelings of guilt can quietly interfere with diabetes care, even when someone is taking the right medications. Because of …